Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease

Journal of Biological Chemistry(2021)10.1016/j.jbc.2021.101331Source: DataRank Database

A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease is a research paper published in Journal of Biological Chemistry (2021). On theSindex it has a DataRank of 0. It has been cited 27 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access27 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 2.14)OA: goldTopics (68)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Marta Melis ORCID,Changyuan Lu ORCID,Andrew Rappa,Tuo Zhang ORCID,José Jessurun ORCID

Live enrichment

PubMed:34688661 PMC:PMC8626588 OpenAlex:https://openalex.org/W3205983312

National Institutes of Health

Grant: R01DK113088

NCI NIH HHS

Grant: T32 CA062948

National Institutes of Health

Grant: 5R01DK113088-08

Gene Nutrient Interactions in Kidney Function

Weill Cornell Medicine

FWCI

2.14

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.jbc.2021.101331

publisherhttps://doi.org/10.1016/j.jbc.2021.101331

publisherhttps://api.elsevier.com/content/article/PII:S0021925821011376?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0021925821011376?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34688661

Fields of Study

Liver Disease Diagnosis and TreatmentLipid metabolism and disordersPeroxisome Proliferator-Activated Receptors0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsBenzoatesLiverMaleMetabolomeMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseReceptors, Retinoic AcidThiazolesTranscriptomeMice

MeSH Terms

AnimalsBenzoatesLiverMaleMice, Inbred C57BLThiazolesReceptors, Retinoic AcidMiceMetabolomeTranscriptomeNon-alcoholic Fatty Liver Disease

Keywords

SteatohepatitisFatty liverMetabolomeTranscriptomeLipid metabolismEndocrinologyFatty acid metabolismInternal medicineLipotoxicitySteatosisChemistryAgonistCD36Retinoic acidBiologyReceptorBiochemistryMetabolismMedicineMetaboliteDiseaseGene expressionInsulin resistanceGeneDiabetes mellitusVitamin ANonalcoholic fatty liver diseaseRetinoic acid receptorLiver SteatosisFructose MetabolismMaleReceptors, Retinoic AcidBenzoatesMice, Inbred C57BLThiazolesMiceLiverNon-alcoholic Fatty Liver DiseaseAnimalsResearch Article

Sustainable Development Goals

SDG 0: Good health and well-being

A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease

FAIR Checklist

Authors (8)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)